Neurent Medical wins FDA nod for next-gen chronic rhinitis treatment

Neurent Medical announced that it received FDA 510(k) clearance for its next-generation Neuromark system for chronic rhinitis.

The latest advancement in the Neuromark platform delivers a new level of control, confirmation and confidence for otolaryngologists.

Galway, Ireland-based Neurent designed the system to optimize the treatment of posterior nasal nerves. It provides real-time feedback, guides proper electrode placement and confirms successful treatment delivery.

Neuromark features a flexible shaft and atraumatic leaflets that conform to the patient anatomy. This enables physicians to reach challenging areas in the nasal cavity while maximizing treatment coverage. The system delivers impedance-controlled, low-power radiofrequency (RF) energy to disrupt parasympathetic nerve signals. This addresses the key symptoms of chronic rhinitis, such as persistent nasal congestion and rhinorrhea (runny nose).

Sign up for Blog Updates